IRVINE, Calif., June 8, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company") announced today
that its industry leading cryogenic logistics solutions, including cryogenic shipping, logistics support and chain of condition
monitoring, are supporting Tissue Solutions ("Tissue Solutions") as it transports products from their global network
of more than 100 locations. Tissue Solutions is a leading supplier of human bio specimens to the pharmaceutical and biotech
industries worldwide, specializing in the supply of high quality, ethically sourced human tissue and bio fluids for clinical
trial programs.
Tissue Solutions is utilizing Cryoport's logistics management platform, proprietary Cryoport Express® dry vapor dewars and
advanced Smart Pak II™ condition monitoring systems to ship isolated human cells and cryopreserved cell lines from international
collection sites to clients across the globe. The Smart Pak II™ Condition Monitoring System is engineered to work in tandem with
Cryoport's data management platform, the Cryoportal™, which provides automated alerts regarding changes in required conditions,
including deviations from estimated transit times, temperature excursions, potential temperature excursions, as well as shipper
condition and openings. Cryoport's custom end-to-end solutions provides Tissue Solutions' cell lines with the most advanced
cryogenic logistics solution anywhere including constant monitoring during the entire logistics process.
Morag McFarlane, CEO of Tissue Solutions stated, "We use Cryoport to ship isolated human cells
and cryopreserved cell lines, including PBMCs and other immune cell subsets. Shipping at cryogenic temperatures with Cryoport's
solution offers our clients the best option to minimize temperature fluctuations which can have a detrimental impact on cell
integrity. Also, Cryoport's custom solutions significantly broaden our reach and the number of sites we can offer to our clients.
Further, it affords our clients the option to select samples based on a wide range of specific donor demographic characteristics
or screen multiple lots to find the sample that works best for their research, ensuring they get the specific samples they need,
and are not restricted geographically."
Jerrell Shelton, CEO of Cryoport, said, "Cryoport is proud to be supporting Tissue Solutions,
which is a leading supplier of ethically sourced human bio specimens. Tissue Solutions' services provide an indispensable link
for a number of pharmaceutical and biotech companies for preclinical research and safety testing of drugs. Tissue Solutions
depends on the support that only Cryoport can bring in supporting its highly successful services with Cryoport's advanced
cryogenic logistics expertise and technology including our highly engineered and validated cryogenic cold chain shippers
accompanied by crucial real-time and archived information."
About Tissue Solutions Limited
Tissue Solutions is a virtual biobank, sourcing ethically acquired, fully consented tissue from our extensive global
network. Our collaborating partners include direct hospital sources, commercial biobanks, and charities, as well as prospective
post-mortem organ and tissue collection agencies. We are an ISO 9001:2008 certified company, and offer a single access point for
a wide range of diseased and normal tissues in fresh, frozen, and FFPE formats. We guarantee the quality of our samples, and
continually review our suppliers for their product and service provision. Our products include: fresh human tissues & bio
fluids, fresh human bloods & bio fluids, customized prospective collection, fresh human skin, banked human diseased &
normal samples, freshly isolated human cells and primary cell lines, including PBMCs and FDA/EMEA panels of normal tissues. Our
services include: Biomarker Development, Antibody Support, Histology & IHC, and Patient-derived Xenograft models. For more
information, visit www.tissue-solutions.com.
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its
purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. The Company provides
leading edge logistics solutions for biologic materials, such as immunotherapies, stem cells, CAR-T cells and reproductive cells
for clients worldwide. Cryoport actively supports points-of-care, CRO's, central laboratories, pharmaceutical companies, contract
manufacturers and university researchers. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and
more, please click to download from your iPhone and
iPad or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s
intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's
actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results
to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic
conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical
development risks. The company's business could be affected by a number of other factors, including the risk factors listed from
time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended
March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking
statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise
any forward-looking statements in this press release.
Logo - http://photos.prnewswire.com/prnh/20160524/371732LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cryoport-signs-strategic-agreement-to-support-tissue-solutions-transportation-of-human-cells-and-cryopreserved-cell-lines-300281072.html
SOURCE Cryoport, Inc.